- In December 2024, a clinical trial led by the Hospital del Mar Medical Research Institute demonstrated that the molecule AEF0217, developed by Aelis Farma, significantly improves cognitive function in individuals with Down syndrome. The study's success paves the way for an international Phase II trial to determine optimal dosing and further assess functional benefits
- In February 2024, Invitae Corporation announced the completion of its sale of non-invasive prenatal screening (NIPT) and carrier screening assets to Natera. This strategic move allows Invitae to focus on its core strengths in clinical germline genetic information, while Natera expands its capabilities in reproductive health diagnostics
- In March 2024, Sanofi launched an awareness campaign for World Down Syndrome Day, encouraging employees to wear mismatched socks to symbolize the extra chromosome in individuals with Down syndrome. This initiative aimed to promote inclusion and raise awareness about the condition
- In April 2024, Roche Diagnostics introduced advancements in prenatal screening technologies, including the Harmony Prenatal Test, which assesses the risk of Down syndrome and other chromosomal disorders. These innovations aim to provide expectant parents with more accurate and accessible testing options
- In May 2024, Plex Pharmaceuticals initiated a research program focusing on therapies to address developmental delays associated with Down syndrome. The program aims to explore new treatment avenues to enhance the quality of life for individuals with the condition
